Table 5 Change from baseline in patient reported outcomes by the ACR responder criteria in the abatacept treatment group
ACR20ACR50ACR70
Yes (n = 169)No (n = 220)Yes (n = 63)No (n = 326)Yes (n = 29)No (n = 360)
Activity limitation−9.2 (12.0)−1.8 (10.7)−12.8 (11.8)−3.9 (11.4)−15.0 (12.3)−4.5 (11.6)
Fatigue−32.6 (27.7)−4.1 (24.2)−45.7 (28.3)−10.9 (26.1)−52.0 (29.8)−13.7 (27.5)
Sleep quality−11.5 (17.1)−3.8 (15.8)−14.3 (18.7)−5.8 (16.1)−16.9 (24.0)−6.4 (15.9)
SF-36 Physical functioning7.5 (10.3)1.2 (9.0)14.1 (9.2)2.0 (9.0)15.8 (9.4)3.0 (9.5)
SF-36 Role-physical9.4 (12.1)1.2 (8.7)15.4 (11.6)2.7 (9.7)17.8 (11.6)3.7 (10.3)
SF-36 Bodily pain12.4 (9.8)2.0 (7.6)18.2 (9.4)4.2 (8.5)21.7 (10.1)5.3 (9.0)
SF-36 General health6.0 (8.6)0.5 (7.3)9.0 (9.0)1.7 (7.6)11.6 (10.0)2.2 (7.8)
SF-36 Vitality9.9 (10.4)1.2 (9.3)13.5 (11.9)3.4 (9.6)14.7 (12.8)4.2 (10.1)
SF-36 Social functioning10.6 (11.7)1.7 (10.6)14.5 (11.8)3.8 (11.2)17.8 (13.2)4.6 (11.3)
SF-36 Role-emotional7.0 (16.9)3.4 (15.0)10.4 (17.6)3.9 (15.4)16.7 (15.3)4.0 (15.6)
SF-36 Mental health5.3 (10.4)1.9 (9.6)8.7 (11.8)2.4 (9.4)10.4 (14.3)2.8 (9.5)
SF-36 Physical component9.7 (9.7)0.7 (7.0)15.9 (9.2)2.5 (7.7)17.5 (9.5)3.6 (8.6)
SF-36 Mental component6.6 (11.7)2.3 (10.6)8.7 (13.2)3.3 (10.7)12.4 (13.2)3.5 (10.9)
  • Values are mean (SD).

  • ACR20/ACR50/ACR70, >20%/50%/70% improvement in rheumatoid arthritis signs and symptoms defined by American College of Rheumatology criteria.